ETANA AND BOGOR CITY GOVERNMENT STRENGTHEN CHILD HEALTH THORIUGH VACCINE
Bogor, April 30, 2025 – In commemoration of World Immunization Week 2025, PT Etana Biotechnologies Indonesia (Etana), in collaboration with the Bogor City Government, conducted a vaccination program for children. A total of 2.081 doses of Hepatitis A and PCV13 vaccines were administered during a series of events held at Bogor City Hall, Boxies Mall, and several schools across the city.
“As a vaccine manufacturer, Etana plays an important role in ensuring safe, effective, and affordable access to vaccines for the Indonesian population. In line with National Immunization Week 2025, Etana provided 1.081 doses of the Hepatitis A vaccine for elementary school (SD) students and 1.000 doses of the PCV13 vaccine for children in early childhood education (PAUD) and kindergarten (TK),” said Indra Lamora, Director of Etana’s Anti-Infectious Business Unit.
Indra highlighted that one of the key challenges in expanding immunization coverage in Indonesia is the low level of public understanding and trust in vaccination. To address this, Etana continues to collaborate with various stakeholders—including the Government, healthcare institutions, educational organizations, the Indonesian National Sports Committee (KONI), and other relevant partners—to strengthen public awareness and confidence in immunization.
“We believe the future of Indonesia’s health will be stronger through close collaboration between the government, industry, academia, and the community in building a sustainable healthcare ecosystem,” Indra added.
This collaboration also reflects Etana’s commitment to supporting government efforts to achieve national self-reliance in the biopharmaceutical sector. By producing high-quality, affordable, and innovative biological products and vaccines, Etana aims to strengthen national resilience and preparedness against infectious diseases and potential future pandemics.
“Going forward, Etana will continue to prioritize the production of locally made vaccines as a strategic step to reduce Indonesia’s dependence on imported vaccines,” Indra concluded.
On the same occasion, Bogor Mayor Dedie Rachim welcomed the initiative and emphasized the importance of building awareness to support a healthier future generation.
“Etana Biotechnologies has taken the initiative to raise awareness. Without awareness of vaccination, healthy living, and productivity, our children will face challenges in competing globally. With vaccines, God willing, their quality of life will improve,” said Dedie.
About Etana
Established in 2014, Etana is an Indonesian biopharmaceutical company that researches, manufactures and markets biological therapies for the Southeast Asian market. With a mission to serve patients by providing high quality, affordable, and innovative therapies, the company has built state-of-the-art local production facility that meet international and Indonesian FDA standards. The facility is able to produce biological therapy with halal certification from the Indonesian Ulema Council (MUI). Etana aspires to become a leading biopharmaceutical company in the ASEAN region through aggressive expansion in production capacity and product development, with a primary focus on oncology and vaccine products.
Etana is led by a local management team who come from various international and domestic educational backgrounds and have strong experience in the biopharmaceutical industry and are supported by a team of international investors and leading biopharmaceutical companies. Etana aims to provide innovative yet affordable therapies through local production, to support Indonesian government programs and larger market demands. Etana is currently a leading biotech company in Indonesia committed to the research and manufacture of monoclonal antibodies, mRNAs and other biological platforms. For more information on Etana, visit: www.id.etanabiotech.com.